ScinoPharm Taiwan Ltd
TWSE:1789

Watchlist Manager
ScinoPharm Taiwan Ltd Logo
ScinoPharm Taiwan Ltd
TWSE:1789
Watchlist
Price: 23.5 TWD -0.63% Market Closed
Market Cap: 18.6B TWD
Have any thoughts about
ScinoPharm Taiwan Ltd?
Write Note

ScinoPharm Taiwan Ltd
Unrealized Security Profit/Loss

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ScinoPharm Taiwan Ltd
Unrealized Security Profit/Loss Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Unrealized Security Profit/Loss CAGR 3Y CAGR 5Y CAGR 10Y
ScinoPharm Taiwan Ltd
TWSE:1789
Unrealized Security Profit/Loss
-NT$118.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Y
YungShin Global Holding Corp
TWSE:3705
Unrealized Security Profit/Loss
NT$53.9m
CAGR 3-Years
50%
CAGR 5-Years
48%
CAGR 10-Years
N/A
Formosa Laboratories Inc
TWSE:4746
Unrealized Security Profit/Loss
NT$3.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-29%
S
SCI Pharmtech Inc
TWSE:4119
Unrealized Security Profit/Loss
NT$18.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Lotus Pharmaceutical Co Ltd
TWSE:1795
Unrealized Security Profit/Loss
-NT$102.5m
CAGR 3-Years
24%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Standard Chem & Pharm Co Ltd
TWSE:1720
Unrealized Security Profit/Loss
NT$465m
CAGR 3-Years
95%
CAGR 5-Years
42%
CAGR 10-Years
N/A
No Stocks Found

ScinoPharm Taiwan Ltd
Glance View

Market Cap
18.6B TWD
Industry
Pharmaceuticals

ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.

Intrinsic Value
16.51 TWD
Overvaluation 30%
Intrinsic Value
Price

See Also

What is ScinoPharm Taiwan Ltd's Unrealized Security Profit/Loss?
Unrealized Security Profit/Loss
-118.3m TWD

Based on the financial report for Jun 30, 2024, ScinoPharm Taiwan Ltd's Unrealized Security Profit/Loss amounts to -118.3m TWD.

What is ScinoPharm Taiwan Ltd's Unrealized Security Profit/Loss growth rate?
Unrealized Security Profit/Loss CAGR 1Y
-36%

Over the last year, the Unrealized Security Profit/Loss growth was -36%.

Back to Top